HMG CoA reductase inhibitor medications combined wih CoEnzyme Q-10
OwnerMilton Hammerlyinventor
Life of this patent
Estimating the term…
Abstract
Provided herein are medicinal compositions of matter that comprise an HMG CoA reductase inhibitor medication component and a CoEnzyme Q-10 component. Through use of the compositions of the invention a reduction of potential adverse physiologic effects is observed in the treatment of hypercholesterolemia, mixed dyslipidemia, and coronary artery disease. The invention also provides procedures for administering the composition to a patient who is afflicted with hypercholesterolemia, mixed dyslipidemia, or coronary artery disease.
Claims31
1) A medicinal composition useful in the treatment of hypercholesterolemia, mixed dyslipidemia and coronary artery disease comprising:
- a) an HMG CoA reductase inhibitor component;
- and
- b) a CoEnzyme Q-10 component.
13) A method of treating a patient showing symptoms of hypercholesterolemia, mixed dyslipidemia and coronary artery disease, the method comprising:
- administration to said patient of a therapeutically effective amount of an HMG
- CoA reductase inhibitor component in synergistic combination with a
- therapeutically effective amount of a Co-Enzyme Q-10 component, wherein the HMG CoA reductase inhibitor component is administered to alleviate symptoms of hypercholesterolemia, mixed dyslipidemia, or coronary artery disease.
31) A process for treating hypercholesterolemia, mixed dyslipidemia, and coronary artery disease comprising the steps of
- a) providing a comprising:
- i) an IMG CoA reductase inhibitor;
- and
- ii) a CoEnzyme Q-10, and
- b) introducing said composition into a human body that is afflicted with a hypercholesterolemia, mixed dyslipidemia, or coronary artery disease.
Dependencies are inferred from the claim text.